Zacks: Brokerages Expect BioScrip Inc (NASDAQ:BIOS) Will Post Quarterly Sales of $185.73 Million

Brokerages expect that BioScrip Inc (NASDAQ:BIOS) will post sales of $185.73 million for the current quarter, Zacks reports. Two analysts have made estimates for BioScrip’s earnings, with estimates ranging from $185.46 million to $186.00 million. BioScrip reported sales of $175.79 million in the same quarter last year, which would suggest a positive year over year growth rate of 5.7%. The business is expected to report its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that BioScrip will report full-year sales of $752.83 million for the current year, with estimates ranging from $752.66 million to $753.00 million. For the next fiscal year, analysts expect that the firm will post sales of $802.56 million, with estimates ranging from $796.00 million to $809.11 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that that provide coverage for BioScrip.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $178.96 million during the quarter, compared to analyst estimates of $179.23 million. The firm’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.12) earnings per share.

Several analysts have recently issued reports on the company. TheStreet cut BioScrip from a “c-” rating to a “d” rating in a research note on Wednesday, April 3rd. Zacks Investment Research upgraded BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Thursday, June 20th. BidaskClub upgraded BioScrip from a “sell” rating to a “hold” rating in a research note on Thursday, May 9th. Barrington Research reiterated a “buy” rating and issued a $4.00 price objective on shares of BioScrip in a research note on Friday, May 3rd. Finally, Canaccord Genuity reduced their price objective on BioScrip from $5.00 to $3.50 and set a “buy” rating on the stock in a research note on Monday, March 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. BioScrip presently has a consensus rating of “Buy” and a consensus target price of $4.60.

Shares of NASDAQ BIOS traded down $0.02 during mid-day trading on Friday, hitting $2.30. The company had a trading volume of 14,757 shares, compared to its average volume of 777,512. The stock has a market cap of $294.86 million, a P/E ratio of -4.65 and a beta of 0.49. BioScrip has a 1-year low of $1.56 and a 1-year high of $4.14. The business’s 50-day moving average price is $2.12.

A number of large investors have recently bought and sold shares of BIOS. BlackRock Inc. increased its holdings in BioScrip by 28.8% in the fourth quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock valued at $35,013,000 after buying an additional 2,191,490 shares during the last quarter. Rothschild & Co. Asset Management US Inc. increased its holdings in BioScrip by 68.1% in the first quarter. Rothschild & Co. Asset Management US Inc. now owns 3,812,471 shares of the company’s stock valued at $7,625,000 after buying an additional 1,545,050 shares during the last quarter. Deutsche Bank AG increased its holdings in BioScrip by 104.5% in the fourth quarter. Deutsche Bank AG now owns 724,410 shares of the company’s stock valued at $2,584,000 after buying an additional 370,177 shares during the last quarter. Two Sigma Investments LP increased its holdings in BioScrip by 81.2% in the fourth quarter. Two Sigma Investments LP now owns 767,882 shares of the company’s stock valued at $2,741,000 after buying an additional 344,013 shares during the last quarter. Finally, Stephens Inc. AR purchased a new position in BioScrip in the first quarter valued at $405,000. 78.62% of the stock is currently owned by hedge funds and other institutional investors.

BioScrip Company Profile

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

See Also: Bear Market

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.